Injection drug use and preventive measures: A comparison of Canadian and Western European jurisdictions over time

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 12, 2000, Pages 1709-1713

  Fischer, Benedikt ^a,b   Rehm, Jürgen ^a,b,c,d   Blitz Miller, Tamara ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CAUSE OF DEATH; DRUG INJECTION VOLUME; DRUG USE; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; REVIEW; SYRINGE; VIRUS TRANSMISSION; WESTERN EUROPE;

EID: 0034643772     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. 1. Fischer B, Kendall P, Rehm J, Room R. Charting WHO - goals for licit and illicit drugs for the year 2000: Are we "on track"? Public Health 1997;111:271-5.
2. 1. Single F., Robson L, Rehm J, Xiaodi X. Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada. Am J Public Health 1999;89:385-90.
3. 3. World Bank. World development report 1993 - investing in health. New York: World Bank/Oxford University Press; 1993.
4. 4. Jones ST, Vlahov D. Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:S1-5.
5. 5. Wodak A, Lurie P. A tale of two countries: attempts to control HIV among injecting drug users in Australia and the United States. J Drug Issues 1996;27:117-34.
6. 6. Klingemann H, Hunt G, editors. Drug treatment systems in an international perspective: drugs, demons, and delinquents. London: Sage; 1998.
7. 7. Nadelmann E, McNeely J, Drucker E. Harm reduction drug control strategies: a global perspective. In: Lowinson J, Ruiz P, Millman R, editors. Substance abuse: a comprehensive textbook. Baltimore: Williams & Wilkins; 1997. p. 22-39.
8. 8. Fischer B. Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses [review]. J Public Health Policy 1995;16:389-411.
9. 9. Fischer B, Rehm J. The case for a heroin substitution treatment trial in Canada. Can J Public Health 1997;88:367-70.
10. 10. Poulin C, Single G, Fralick P. Canadian Community Epidemiology Network on Drug Use (CCENDU) second national report 1999. Ottawa: Canadian Centre on Substance Abuse; 1999.
11. 11. Millson P, Myers T, Calzavara L, Rea E, Wallace E, Major C, et al. Prevalence of HIV and other bloodborne viruses and associated risk behaviours in Ontario injection drug users (IDU). Toronto: HIV Social, Behavioural and Epidemiological Studies Unit, Faculty of Medicine, University of Toronto; 1998.
12. 12. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:S57-9.
13. 13. Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11:59-65.
14. 14. Millar JS. HIV, hepatitis, and injection drug use in British Columbia - Pay now or pay later? Victoria: Office of Provincial Health Officer; 1998.
15. 15. Bruneau J, Lamothe F, Franco F, Lachance N, Delsy M, Soto J, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997;146:994-1002.
16. 16. Smart RG. AIDS and drug abuse in Canada: current status and information needs. J Drug Issues 1991;21:73-82.
17. 17. HIV, AIDS and injection drug use: a national action plan. Ottawa: Health Canada; 1997.
18. 18. HIV prevalence and incidence in Canada. Ottawa: Division of HIV/AIDS Surveillance, Laboratory Centre for Disease Control, Health Canada; 1999.
19. 19. Drug use in Toronto. Toronto: Research Group on Drug Use; 1999. Available: www.drugctr@city.toronto.on.ca.
20. 20. La toxicomanie à Montréal-Centre: faits et méfaits 1999. Montreal: Régie régionale de la Santé et des Services sociaux; 1999.
21. 21. Cain V. Report of the Task Force into Illicit Narcotic Overdose Deaths in British Columbia. Burnaby (BC): Office of the Chief Coroner, Province of British Columbia; 1994.
22. 22. National report 1998. The Netherlands. Epidemiological situation. Utrecht (The Netherlands): Trimbos Institute, Netherland Institute of Mental Health and Addiction; 1998.
23. 23. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. The HIV epidemic associated with injecting drug use in Europe: geographic and time trends. AIDS 1997;11:1365-74.
24. 24. Derks JTM, Hoekstra MJ, Kaplan CD. Integrating care, cure, and control: the drug treatment system in the Netherlands. In: Klingemann H, Hunt G, editors. Drug treatment systems in an international perspective: drugs, demons, and delinquents. London: Sage Publications; 1998. p. 81-93.
25. 25. De Zwart WM, Mensink C. Alcohol, tabak, drugs en gokken in ciifers. Utrecht (The Netherlands): Netherlands Institute for Alcohol and Drugs; 1993.
26. 26. Van Brussel G. Heroinvergabe in Amsterdam. Praxis und/oder Wissenschaft? In: Westermann B, Bellman G, Jellinek C, editors. Heroinverschreibung: Wirkungen und Nebenwirkungen. Cologne: Deutscher Studien Verlag; 1999. p. 114-23.
27. 27. Dobler-Mikola A, Pfeifer S, .Müller V, Uchtenhagen A. Methadon-und beroinunterstützte Behandlung Opiatabhängiger im Vergleich. Zurich: Institut für Suchtforschung; 1998.
28. 28. Steffen T. Die infektiologische Situation bei intravenös Drogenabhängigen in den Versuchen für eine ärztliche Verschreibung von Betäubungsmitteln (PROVE) unter besonderer Berücksichtigung von Public Health - Aspekten. Zurich: Institut für Suchtforschung; 1998.
29. 29. Klingemann H. Harm reduction and abstinence: Swiss drug policy at a time of transition. In: Klingemann H, Hunt G, editors. Drug treatment systems in an international perspective: drugs, demons, and delinquents. London: Sage Publications; 1998.
30. 30. Rihs-Middel M. Die Heroinvergabe im Spannungsfeld von Forschung und Praxis. In: Westermann B, Bellman G, Jellinek C, editors. Heroinverschretbung: Wirkungen und Nebenwirkungen. Cologne: Deutscher Studien Verlag; 1999. p. 77-113.
31. 31. Simon R, Tauscher M. REITOX focal points Germany - report on the drug situation 1997 (prepared on behalf of the European Monitoring Centre for Drugs and Drug Addiction, Lisbon). Munich: Institut für Therapieforschung; 1998.
32. 32. Kleiber D, Pant A. HIV-needle-sharing-sex: eine sozialepidemiologische Studie zur Analyse der HIV-Prävalenz und riskanter Verhaltensweisen bei i.v.-Drogenkonsumenten. Baden-Baden (Germany): Nomos Verlagsgesellschaft; 1993.
33. 33. Vogt I, Schmid M. Illicit drugs in Germany and the emergence of the modern drug treatment system. In: Klingemann H, Hunt G, editors. Drug treatment systems in an international perspective: drugs, demons, and delinquents. London: Sage Publications; 1998. p. 145-57.
34. 34. Pant A, Söllner R. Epidemiology of HIV in intravenous drug users and public health policy in Germany. J Drug Issues 1996;27:9-41.
35. 35. Epidemiological fact sheet on HIV/AIDS and sexually transmitted diseases. Saint-Maurice (France): Centre européen pour la Surveillance épidémiologique du SIDA; 1999. Available: www.ceses.org/AidsSurv/carte/germany.htm (accessed July 23, 1999).
36. 36. Die Kriminalität in der Bundesrepublik Deutschland: polizeiliche Kriminalstatistik für das Jahr 1998. Bonn (Germany): Presse-und Informationsamt der Bundesregierung; 1999.
37. 37. Weber U, Schneider W. Syringe exchange in Germany. Subst Use Misuse 1998;33:1093-112.
38. 38. Fischer B. Prohibition, prescriptions and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. In press.
39. 39. Methadone treatment statistics, 1988-1996 [provided 1997 Jan 23]. Ottawa: Bureau of Drug Surveillance, Health Protection Branch, Health Canada.
40. 40. Hankins CA. Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse 1998;33:1129-45.
41. 41. Schechter MT, Strathdee SA, Cornelisse PGA, Currie S, Patrick DM, Rekart ML, et al. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak AIDS 1999;13:F45-51.
42. 42. Canadian HIV/AIDS Legal Network. Injection drug use and HIV: legal and ethical issues. Montreal: The Network; 1999.
43. 43. Coates RA, Rankin JG, Lamothe F, Arshinoff R, Raboud J, Millson ME, et al. Needle sharing behaviour among injection drug users (IDUs) in treatment in Montreal and Toronto, 1988-1989. Can J Public Health 1992;83:38-41.
44. 44. Fischer B, Medved W, Rehm J, Gliksman L. Profile of illicit and untreated opiate users in Toronto, Canada. Addict Res 1999;7(5):377-415.
45. 45. Investigating the medical prescription of heroin. Utrecht (The Netherlands): Central Committee on the Treatment of Heroin Addicts; 1997.
46. 46. Farrell M. A review of the legislation, regulation and delivery of methadone in 12 member states of the European Union. London: European Commission; 1995.
47. 47. Van Ameijden EJC, Walters JK, van den Hoek AR, Coutinho RA. Interventions among injecting drug users: Do they work? AIDS 1995;9:S75-84.
48. 48. Swiss methadone report. Borne/Toronto: Swiss Federal Office of Public Health/Addiction Research Foundation; 1997.
49. 49. Rehm J. Konsumformen und l'erbreitung illegaler Drogen in der Schweiz. In: Fahrenkrug H, Rehm j, Muller H, Klingemann H, et al, editors. Illegale Drogen in der Schweiz 1990-1993. Zurich: Seismo; 1995. p. 13-33.
50. 50. Kalke J, Verthein U, Raschke P. 10 jahre Substitutionstherapie in der Bundesrepublik Deutschland - politsche Entwicklung und Evaluationsergebnisse. Wien Z Suchtforschung 1998;21:47-54.
51. 51. Simon R, Tauscher M, Pfeiffer T. Suchtbericht Deutschland 1999. Hohengehran (Germany): Schneider Verlag; 1999.
52. 52. Drogen-und Suchtbericht 1999: der Drogenbeauftragen der Bundesregierung. Bonn/Berlin: Bundesministerium für Gesundheit; 2000.
53. 53. Harrison L, Hughes A. The validity of self-reported drug use: improving the accuracy of survey estimates. Rockville (MD): National Institute on Drug Abuse; 1997. NIDA Research Monograph 167.
54. 54. Ward J, Hall W, Mattick R. Role of methadone maintenance in optoid dependence. Lancet 1999;353:221-6.
55. 55. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction, National Institutes of Health. Effective medical treatment of opiate addiction. JAMA 1998;280:1936-43.
56. 56. Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 1995;245:114-24.
57. 57. Des Jarlais D, Friedmann P, Hagan H, Friedman S. The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. Am J Public Health 1996;12:1780-5.
58. 58. Hurley SF, Jolley DJ, Klador JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997;349:1797-800.
59. 59. Remis RS, Sutherland DW. The epidemiology of HIV and AIDS in Canada: current perspectives and future needs. Can J Public Health 1993;84:34-8.
60. 60. Strathdee SA, van Ameijden EJC, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS 1998;12:S71-9.
61. 61. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997;349:604-8.